Trastuzumab, a humanized monoclonal antibody (mAb) targeting human epidermal growth factor receptor 2 (HER2), represents a type of chemotherapy that is now a standard approach for patients with HER2-positive advanced gastric cancer. Here, ERBB2 is linked to gastric cancer.